Patient characteristics
| Number of patients | 43 |
| Sex (male/female) | 25/18 |
| Median age, y (range) | 31 (1-53) |
| Diagnosis | |
| Leukemia/myelodysplastic syndrome | 32 |
| Malignant lymphoma | 9 |
| Aplastic anemia | 1 |
| Histiocytosis | 1 |
| Preparative regimen | |
| TBI-based | 33 |
| Busulfan-based | 10 |
| Transplant | |
| Marrow | 25 |
| Blood | 11 |
| Both | 7 |
| Donor | |
| HLA-identical sibling | 14 |
| Mismatched related | 15 |
| Unrelated | 14 |
| GVHD prophylaxis | |
| Tacrolimus-based | 18 |
| Cyclosporine-based | 13 |
| Cyclosporine + T-cell depletion | 7 |
| T-cell depletion + other | 5 |
| Daclizumab regimen | |
| 1 (days 1, 8, 15, 22, 29) | 24 |
| 2 (days 1, 4, 8, 15, 22) | 19 |
| Number of patients | 43 |
| Sex (male/female) | 25/18 |
| Median age, y (range) | 31 (1-53) |
| Diagnosis | |
| Leukemia/myelodysplastic syndrome | 32 |
| Malignant lymphoma | 9 |
| Aplastic anemia | 1 |
| Histiocytosis | 1 |
| Preparative regimen | |
| TBI-based | 33 |
| Busulfan-based | 10 |
| Transplant | |
| Marrow | 25 |
| Blood | 11 |
| Both | 7 |
| Donor | |
| HLA-identical sibling | 14 |
| Mismatched related | 15 |
| Unrelated | 14 |
| GVHD prophylaxis | |
| Tacrolimus-based | 18 |
| Cyclosporine-based | 13 |
| Cyclosporine + T-cell depletion | 7 |
| T-cell depletion + other | 5 |
| Daclizumab regimen | |
| 1 (days 1, 8, 15, 22, 29) | 24 |
| 2 (days 1, 4, 8, 15, 22) | 19 |